New anemia drug enters early human testing
NCT ID NCT05773586
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called APG-5918 in healthy volunteers and people with anemia (low red blood cells). The main goal is to check safety and how the body handles the drug, while also seeing if it can raise hemoglobin levels. About 105 participants will take part to gather initial data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanfang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510515, China
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less be more? testing transfusion limits in ECMO
- A simple blood test trend may flag ICU patients at risk
- Rethinking anemia: does blood hemoglobin tell the whole story?
- A simple nutrient may shield Babies' brains from iron deficiency
- School health rooms and trained teachers: a new hope for Zambia's children?
- Can a pill replace EPO shots for anemia in kidney disease?